The FDA granted supplemental approval to Calquence (acalabrutinib), atreatment for adults with chronic lymphocytic leukemia (CLL) or small lyphocytic lymphoma (SLL). This approval was part of Project Orbis, a collaboration among the FDA, the Australian Therapeutic Goods Administration, and Health Canada, marking the second approval under the program. As a global provider of clinical packaging and courier services, Yourway has a breadth of knowledge of international regulations and supports more initiatives to harmonize regulations across nations.
6681 Snowdrift Road
Toll Free:
Fax:
Email:
